AMYLYX PHARMACEUTICALS
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain. The company features a drug designed to prevent nerve cell death and degeneration.
AMYLYX PHARMACEUTICALS
Industry:
Biotechnology Medical Neuroscience Pharmaceutical
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.amylyx.com
Total Employee:
251+
Status:
Active
Total Funding:
448.45 M USD
Technology used in webpage:
Google Google Cloud DNSSEC Facebook Sharer Microsoft AWS Global Accelerator Amazon Route 53 Microsoft Azure Google Cloud Global Multi-Region Mailgun
Similar Organizations
Acceleron Pharma
Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
Braingrade
Braingrade developing a new solution for patients with Alzheimer’s Disease.
Cure Alzheimer's Fund
Cure Alzheimer's Fund is involved in the funding of the research on preventing, slowing and reversing Alzheimer's disease.
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals focuses on improving kinase inhibitor treatments.
Kala Pharmaceuticals
Kala Pharmaceuticals develops novel treatments for diseases that affect mucosal tissues.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
683 CAPITAL
683 CAPITAL investment in Series C - Amylyx Pharmaceuticals
aMoon Fund
aMoon Fund investment in Series C - Amylyx Pharmaceuticals
Perceptive Advisors
Perceptive Advisors investment in Series C - Amylyx Pharmaceuticals
Woodline Partners
Woodline Partners investment in Series C - Amylyx Pharmaceuticals
Verition Fund Management
Verition Fund Management investment in Series C - Amylyx Pharmaceuticals
Morningside Venture Investments
Morningside Venture Investments investment in Series C - Amylyx Pharmaceuticals
Polaris Founders Capital
Polaris Founders Capital investment in Series C - Amylyx Pharmaceuticals
Belinda Termeer
Belinda Termeer investment in Series C - Amylyx Pharmaceuticals
Marshall Wace
Marshall Wace investment in Series C - Amylyx Pharmaceuticals
Tybourne Capital Management
Tybourne Capital Management investment in Series C - Amylyx Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.amylyx.com Semrush global rank: 2.1 M Semrush visits lastest month: 9.71 K
- Host name: ec2-23-21-71-204.compute-1.amazonaws.com
- IP address: 23.21.71.204
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Amylyx Pharmaceuticals"
Home | Amylyx
Everything we do at Amylyx is centered around those living with diseases with high unmet needs and their loved ones. We are on a mission to discover and develop innovative treatments and …See details»
Our Company - Amylyx
Amylyx is a global pharmaceutical company based in Cambridge, Massachusetts, that is dedicated to the discovery and development of potential treatments for neurodegenerative diseases.See details»
Leadership Team - Amylyx
We’ve made some great strides toward making a difference in patients’ lives — and we’re just getting started. If you’d like to join us in our mission, learn more about our culture and current …See details»
Amylyx - The Org
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.See details»
Amylyx's Board of Directors - Team members and org chart - The …
Chair of the Scientific Adviso... It takes less than ten minutes to set up your company page. It’s free to use - try it out today. Amylyx's Board of Directors includes Rudolph Tanzi and 6 others.See details»
Maker of ALS drug pulls Relyvrio off the market, …
May 15, 2024 · Justin Klee and Josh Cohen, who started Amylyx while they were students at Brown University, announced that the company would voluntarily stop selling an ALS drug that had brought in $380 million...See details»
Josh Cohen - Co-CEO & Co-Founder at Amylyx - The Org
Josh co-invented AMX0035 and has overseen the growth of Amylyx from its start as a concept dreamed up in a dorm room to its status now as a pre-commercial stage pharmaceutical company. Together with Justin, Josh has raised nearly …See details»
Amylyx Pharmaceuticals - Crunchbase Company Profile …
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain. The company features a drug designed to prevent nerve cell death and degeneration. Products and ServicesSee details»
Investors | Amylyx Pharmaceuticals, Inc.
Nov 7, 2024 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Oct. 15, 2024-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the …See details»
Community Resources - Amylyx
Our mission is to improve the lives of those living with neurodegenerative diseases, whether it's by making strides in developing new treatments, building out a strong community, or providing the resources and support you need.See details»
Why Amylyx is pulling ALS drug Relyvrio from US …
Apr 4, 2024 · WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly …See details»
ALS Association, I AM ALS Call on Amylyx, FDA to Make Promising …
Dec 30, 2020 · The ALS Association and I AM ALS have launched a petition calling on the FDA and Amylyx Pharmaceuticals to bring AMX0035, a promising new drug developed by Amylyx, …See details»
ALS Association Applauds Amylyx's AMX0035 Announcement, …
Sep 15, 2021 · Following Amylyx’s announcement that it intends to submit a New Drug Application (NDA) for AMX0035, The ALS Association today urges the Food and Drug …See details»
Amylyx Pharmaceuticals Announces AMX0035 Demonstrated …
Dec 17, 2019 · Amylyx Pharmaceuticals, Inc. is a pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other …See details»
Amylyx's ALS drug finally scores FDA approval, but that's just the …
Sep 29, 2022 · After a long road filled with scrutiny and uncertainty, Amylyx’s amyotrophic lateral sclerosis (ALS) drug, known as AMX0035, has finally scored FDA approval. The drug, now …See details»
News - Amylyx
From clinical trials to corporate announcements, we're proud to share our recent updates and progress. Scroll below to see what we've been up to, or contact the team for further …See details»
Amylyx Pharmaceuticals: Management Ambitiously Navigates …
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is a US pharmaceutical company engaged in developing medicines for diseases with high unmet needs, particularly in the field of ALS.See details»
Resources - Amylyx
Read about the latest developments in our research, ongoing clinical trials, and what’s on the horizon for Amylyx.See details»
6 Analysts Assess Amylyx Pharma: What You Need To Know
Jun 24, 2024 · Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other …See details»
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ …
Sep 29, 2022 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug …See details»